{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:04:57Z","timestamp":1784297097478,"version":"3.55.0"},"reference-count":37,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CIHR, F17-03454"],"award-info":[{"award-number":["CIHR, F17-03454"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000204","name":"Vancouver Foundation","doi-asserted-by":"publisher","award":["UNR18-0005"],"award-info":[{"award-number":["UNR18-0005"]}],"id":[{"id":"10.13039\/501100000204","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Canada is currently experiencing a problematic opioid crisis with increasing mortality rates. Traditional randomized controlled trials (RCTs) that examine the effectiveness of pharmacological treatment options for people with opioid use disorder (OUD) are challenging to conduct. An increasingly popular methodology is through the implementation of emulated clinical trials, a methodology in which key elements of a \u201ctarget\u201d RCT are replicated using previously collected healthcare-based data. They can possibly address some of the common challenges found in the conduct of RCTs, such as prolonged timelines, high cost, and poor participant recruitment. In effect, emulated trials accelerate knowledge generation by producing real-world evidence that can be akin to phase 3 effectiveness trials, without any need to recruit live participants or administer investigational products. During the COVID-19 pandemic, several trials were stopped due to increased pandemic-related research restrictions, leaving important questions about OUD treatment unanswered. In this commentary, we describe the transition of a traditional RCT to an emulated trial spurred by challenges posed by the COVID-19 pandemic. We describe our transition using a notable published framework with regards to the population sample, interventions, outcomes, and proposed analyses. This commentary aims to help other researchers and trialists apply emulated trials in substance use research and beyond, emphasizing the role of this methodology in clinical research and advancing scientific knowledge that could be otherwise lost or unattainable.<\/jats:p>","DOI":"10.1177\/29767342241279167","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T02:58:56Z","timestamp":1742007536000},"page":"384-390","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Redesigning a Stopped Clinical Trial as an Emulated Trial Using Real-World Data to Explore the Effectiveness of Slow-Release Oral Morphine as a Treatment for Opioid Use Disorder"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1957-5336","authenticated-orcid":false,"given":"Rohan","family":"Anand","sequence":"first","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, BC, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Penta","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zishan","family":"Cui","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Fairbairn","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, BC, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-7049","authenticated-orcid":false,"given":"M. Eugenia","family":"Socias","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, BC, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","unstructured":"Gomes T Greaves S Martins D et al. Latest Trends in Opioid-Related Deaths in Ontario: 1991 to 2015. Ontario Drug Policy Research Network. April 2017. Accessed April 26 2017. http:\/\/odprn.ca\/wp-content\/uploads\/2017\/04\/ODPRN-Report_Latest-trends-in-opioid-related-deaths.pdf","DOI":"10.31027\/ODPRN.2017.01"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2014.301966"},{"key":"e_1_3_3_4_2","unstructured":"Anand R Socias ME. The roots of the North American opioid crisis and 3 key strategies for stopping it. The Conversation. 2023. Accessed February 16 2024. https:\/\/theconversation.com\/the-roots-of-the-north-american-opioid-crisis-and-3-key-strategies-for-stopping-it-213716"},{"key":"e_1_3_3_5_2","unstructured":"Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid- and Stimulant-related Harms in Canada. Public Health Agency of Canada; June 2022. Accessed August 8 2022. https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011117.pub3"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000075"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03140.x"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5945"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"e_1_3_3_11_2","volume-title":"Methadone treatment for people who use fentanyl: recommendations","author":"Bromley L","year":"2021","unstructured":"Bromley L. Methadone treatment for people who use fentanyl: recommendations. Tor METAPHI; 2021."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.12333"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-017-0783-9"},{"key":"e_1_3_3_14_2","volume-title":"A guideline for the clinical management of opioid use disorder","author":"British Columbia Centre on Substance Use","year":"2017","unstructured":"British Columbia Centre on Substance Use. A guideline for the clinical management of opioid use disorder. British Columbia Centre on Substance Use; 2017."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0000000000000288"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000368572"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009879.pub2"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025799"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.001128.x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.105993"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.04.005"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39465.451748.AD"},{"key":"e_1_3_3_24_2","volume-title":"COVID-19 two years on: persistent symptoms of clinical trial disruption trouble certain therapy areas","author":"Hillman A","year":"2022","unstructured":"Hillman A, Castaneda R. COVID-19 two years on: persistent symptoms of clinical trial disruption trouble certain therapy areas. Clinical Trials Arena; 2022;"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.26523"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068729"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102840"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6228"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4672"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.4103\/picr.PICR_206_19"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.14943"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051718"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3845"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-022-01609-6"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/17407745231154215"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071108"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.4073"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241279167","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342241279167","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241279167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:50:24Z","timestamp":1777600224000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342241279167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/29767342241279167"],"URL":"https:\/\/doi.org\/10.1177\/29767342241279167","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]}}}